Sign in
Not yet taking people in United StatesPhase 1

Primary Sclerosing Cholangitis After Liver Transplant With Oral Vancomycin

Key facts

Who runs it
Yael R. Nobel
Where
New York, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
21 people, planned
Started
Nov 2026
Expected to end
Nov 2030
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Oral Vancomycin
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (18)Hide the full registry criteria

Who can take part

  • Age ≥ 18 years
  • Ability to provide written, informed consent
  • History of orthotopic liver transplantation within 1 to 10 years prior to enrollment (i.e. study drug initiation)
  • Diagnosis of PSC as the underlying liver disease leading to liver transplantation, based on compatible imaging findings (magnetic resonance cholangiopancreatography [MRCP], endoscopic retrograde cholangiopancreatography [ERCP], percutaneous transhepatic cholangiogram [PTC]), liver histology, and/or clinician judgment
  • Subjects with or without IBD may be enrolled. IBD diagnosis with a minimum disease duration of 6 months as assessed by endoscopy/histology. IBD should be in clinical remission or mildly active according to accepted clinical scores and/or clinician judgment
  • Stable liver graft function, as determined by ALL of the following criteria:; No episodes of acute rejection within 6 months prior to enrollment, based on liver histology and/or clinical signs or symptoms; No episodes of cholangitis within 6 months prior to study enrollment, based on positive bacterial cultures, compatible imaging, and/or clinical signs or symptoms; No intervention for biliary obstruction (e.g. ERCP, PTC, surgical intervention) within 6 months prior to study enrollment; Stable liver biochemistries within 6 months prior to study enrollment, as determined by: ALP <5x ULN; Absence of histologic or imaging findings suggestive of cirrhosis

Who cannot take part

  • History of colon resection at any time prior to study enrollment or presence of ileal/colonic diversion within 12 months prior to study enrollment
  • Documented VRE infection within 12 months prior to study enrollment
  • Documented C. difficile infection within 3 months prior to study enrollment
  • Systemic antibiotic exposure within 3 months prior to study enrollment
  • Change in any transplant or IBD-related immunosuppression or its dosing within 30 days prior to study enrollment
  • Currently taking oral vancomycin
  • Treatment with any investigational drug within 3 months prior to study enrollment
  • Allergy or intolerance to vancomycin
  • Any active malignancy
  • Any condition that, in the investigator's judgment, would make participation unsafe or interfere with adherence (e.g., severe frailty, uncontrolled psychiatric disease, inability to adhere to TID dosing)
  • Severe renal dysfunction (eGFR <30 mL/min/1.73 m²) or on dialysis
  • Pregnant or breastfeeding Page 8

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Primary sclerosing cholangitis or liver transplant disorder

Where in United States

  • Columbia UniversityNew York, United StatesContact: Rebecca YehNot yet recruiting

About the trial

What the trial wants to find out

Primary Objective:

Read full original descriptionShow less

* To evaluate safety of a 4-week course of oral vancomycin (250 mg 3 times daily [TID]) in liver transplant recipients who were transplanted for Primary Sclerosing Cholangitis (PSC).

Secondary Objectives:

* To determine tolerability and adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. * To assess vancomycin resistant enterococcus (VRE) colonization status over time. * To assess the impact of oral vancomycin on stool microbiome composition, diversity, and function. * To assess impact of oral vancomycin on microbial metabolite concentrations in blood and stool. * To assess impact of oral vancomycin on liver-related biochemical markers.

The 2 groups in the trial

  • Study Arm - Oral VancomycinTreatment being tested

    Patients in study arm will be assigned to receive study drug.

    Treatment: Oral Vancomycin

  • Control Arm - No DrugNo study treatment, for comparison

    Patients in control arm will be assigned to receive no drug.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Preventing Recurrence of Primary Sclerosing Cholangitis After Liver Transplant (PROP-LT): a Phase 1, Open-label, Controlled Study of Oral Vancomycin
Criteria questions
Built from NCT07945873, who can take part
Record updated
18 November 2026